Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Thiopurine effectiveness in patients with Crohn's disease: a study of genetic and clinical predictive factors.

Koifman E, Karban A, Mazor Y, Chermesh I, Waterman M, Almog R, Ben-Horin S, Eliakim R, Krivoy N, Efrati E, Chowers Y.

Inflamm Bowel Dis. 2013 Jul;19(8):1639-44. doi: 10.1097/MIB.0b013e31828828d3.

PMID:
23669401
2.

Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease.

Mazor Y, Koifman E, Elkin H, Chowers Y, Krivoy N, Karban A, Efrati E.

Curr Drug Saf. 2013 Jul;8(3):181-5.

PMID:
23845145
3.

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.

Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.

Aliment Pharmacol Ther. 2005 Oct 1;22(7):613-26.

4.

Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease.

Park JJ, Cheon JH, Hong SP, Kim TI, Kim WH.

Dig Dis Sci. 2012 Jan;57(1):133-41. doi: 10.1007/s10620-011-1955-9. Epub 2011 Nov 6.

PMID:
22057283
5.

Phenotypic features of Crohn's disease associated with failure of medical treatment.

Moran GW, Dubeau MF, Kaplan GG, Yang H, Seow CH, Fedorak RN, Dieleman LA, Barkema HW, Ghosh S, Panaccione R; Alberta Inflammatory Bowel Disease Consortium.

Clin Gastroenterol Hepatol. 2014 Mar;12(3):434-42.e1. doi: 10.1016/j.cgh.2013.08.026. Epub 2013 Aug 24.

PMID:
23978351
6.

"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease.

Cossu A, Biancone L, Ascolani M, Pallone F, Boirivant M.

J Crohns Colitis. 2013 Jul;7(6):441-50. doi: 10.1016/j.crohns.2012.06.020. Epub 2012 Jul 26.

PMID:
22840925
7.

Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease.

Kariyawasam VC, Selinger CP, Katelaris PH, Jones DB, McDonald C, Barr G, Chapman G, Colliwshaw J, Lunney PC, Middleton K, Wang RR, Huang T, Andrews J, Leong RW.

Inflamm Bowel Dis. 2014 Aug;20(8):1382-90. doi: 10.1097/MIB.0000000000000119.

PMID:
24991785
8.

Thiopurines are associated with a reduction in surgical re-resections in patients with Crohn's disease: a long-term follow-up study in a regional and academic cohort.

van Loo ES, Vosseberg NW, van der Heide F, Pierie JP, van der Linde K, Ploeg RJ, Dijkstra G, Nieuwenhuijs VB.

Inflamm Bowel Dis. 2013 Dec;19(13):2801-8. doi: 10.1097/01.MIB.0000435758.97952.a8.

PMID:
24189041
9.

Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up.

Costantino G, Furfaro F, Belvedere A, Alibrandi A, Fries W.

J Crohns Colitis. 2012 Jun;6(5):588-96. doi: 10.1016/j.crohns.2011.11.007. Epub 2011 Dec 8.

PMID:
22398045
10.

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Prefontaine E, Macdonald JK, Sutherland LR.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD000545. doi: 10.1002/14651858.CD000545.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;4:CD000545.

PMID:
20556747
11.

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Prefontaine E, Macdonald JK, Sutherland LR.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD000545. doi: 10.1002/14651858.CD000545.pub2. Review. Update in: Cochrane Database Syst Rev. 2010;(6):CD000545.

PMID:
19821270
12.

Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates.

Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB.

Gut. 2010 Sep;59(9):1200-6. doi: 10.1136/gut.2009.202101. Epub 2010 Jul 21.

PMID:
20650924
13.

The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.

Papay P, Reinisch W, Ho E, Gratzer C, Lissner D, Herkner H, Riss S, Dejaco C, Miehsler W, Vogelsang H, Novacek G.

Am J Gastroenterol. 2010 May;105(5):1158-64. doi: 10.1038/ajg.2009.673. Epub 2009 Dec 15.

PMID:
20010925
14.

Exploring associations of 6-thioguanine nucleotide levels and other predictive factors with therapeutic response to azathioprine in pediatric patients with IBD using multilevel analysis.

Nguyen TV, Vu DH, Nguyen TM, Lachaux A, Boulieu R.

Inflamm Bowel Dis. 2013 Oct;19(11):2404-10. doi: 10.1097/MIB.0b013e3182a508c6.

PMID:
24013359
15.

Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine.

Lecomte T, Contou JF, Beaugerie L, Carbonnel F, Cattan S, Gendre JP, Cosnes J.

Dis Colon Rectum. 2003 Nov;46(11):1469-75.

PMID:
14605564
17.

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group.

Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23.

PMID:
22271569
18.

The influence of CTGF single-nucleotide polymorphisms on outcomes in Crohn's disease.

Burke JP, O'Connell RM, Lennon G, Doherty GA, Keegan D, O'Donoghue D, Mulcahy H, Hyland J, Winter DC, Sheahan K, O'Connell PR.

Ann Surg. 2013 Nov;258(5):767-73; discussion 773-4. doi: 10.1097/SLA.0000000000000247.

PMID:
24121259
19.

Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease.

Lev-Tzion R, Renbaum P, Beeri R, Ledder O, Mevorach R, Karban A, Koifman E, Efrati E, Muise AM, Chowers Y, Turner D.

J Pediatr Gastroenterol Nutr. 2015 Oct;61(4):404-7. doi: 10.1097/MPG.0000000000000820.

PMID:
25885881
20.

Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.

Hoentjen F, Seinen ML, Hanauer SB, de Boer NK, Rubin DT, Bouma G, Harrell LE, van Bodegraven AA.

Inflamm Bowel Dis. 2013 Feb;19(2):363-9. doi: 10.1002/ibd.23021.

PMID:
22605661
Items per page

Supplemental Content

Write to the Help Desk